Randomized, Double-Blind, Placebo-Controlled Trial of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Asian Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin With or Without a Sulfonylurea (GetGoal-L-Asia)
Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/j.1463-1326.2012.01618.x